Clinical Trials
Eisai and Purdue Pharma Announce Positive Topline Results of...
Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an...
Clinical Trials
GamaMabs Pharma starts a phase 2 study of monoclonal...
GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting the Anti-Müllerian Hormone Receptor II (AMHRII) for the treatment of cancer, announces that it has...
Clinical Trials
Thrombolytic Science Initiates Phase 2 Clinical Trial of its...
Thrombolytic Science, LLC (TSI) today announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of...
Clinical Trials
CRF Health Partners Innovative US Biotech with TrialMax® eCOA...
CRF Health, the leading provider of patient-centered eSource technology solutions for the life sciences industry, announced that its TrialMax® Slate solution has been selected by...
Clinical Trials
Celtaxsys Announces Results of Phase 2 Trial Showing Clinically...
Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, announced top line results of its Phase...
Clinical Trials
Servier and Galapagos announce start of global ROCCELLA Phase...
Servier, an independent international pharmaceutical company, and the company Galapagos NV announce the start of a global Phase 2 trial with S201086/GLPG1972 in knee osteoarthritis...
Clinical Trials
AbbVie Provides Update on Phase 3 Study of Ibrutinib...
AbbVie , a research-based global biopharmaceutical company, announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA®) in untreated diffuse large B-cell lymphoma...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.